McKesson stock faces earnings test as profit growth takes focus

McKesson stock enters a closely watched earnings week as the pharmaceutical distributor prepares to publish fiscal second-quarter 2027 results after the U.S. market close on Wednesday, November 4. The latest Ad-hoc News preview, citing Yahoo Finance and Barchart, puts profit growth at the center of the report.

Profit expectations set a hurdle

The preview says analysts expect diluted earnings of 10.69 US dollars per share, an increase of 8.4 percent from the year-earlier quarter. McKesson has exceeded Wall Street's EPS estimates in each of its last four quarterly reports, raising the importance of the next result and any change in management's outlook.

Analysts expect full-year EPS of 44.71 US dollars, compared with 39.11 US dollars in fiscal 2026. McKesson's adjusted fiscal 2027 earnings guidance remains 44.20 to 45.00 US dollars per share, creating a clear reference point for management commentary after the release.

Recent results raise expectations

McKesson reported fiscal first-quarter revenue of 105.4 billion US dollars and adjusted EPS of 9.93 US dollars on August 5. Those figures exceeded the cited Wall Street estimates of 104.4 billion US dollars for revenue and 9.44 US dollars for adjusted EPS.

The next report will give investors a fresh view of pharmaceutical distribution, specialty care and medical-surgical operations. The key question is whether earnings growth can support the existing full-year outlook through the second half of fiscal 2027.

Trading quote and next catalyst

McKesson stock traded at 896.60 euros on Lang & Schwarz at 16:39 CET on Monday, November 2, 2026. That was 1.31 percent above the 885.00-euro Lang & Schwarz quote cited in the November 2 preview at 12:38 CET.

Follow the real-time quote of McKesson stock for the latest trading level.

The S&P 500 remains the relevant U.S. market backdrop for McKesson stock: Current market reports.

More news and analyses on McKesson stock.